文献速递其他结缔组织病

免疫介导坏死性肌病的当前认识综述

Immune-mediated necrotising myopathy: A critical review of current concepts.
PubMed 文献 · Semin Arthritis Rheum · 2019-04-25

本文综述免疫介导坏死性肌病(IMNM)的病理生理、临床表现、组织学特征与血清学特点。该病以进行性近端肌无力、肌纤维坏死伴再生及肌内淋巴细胞稀少为特征,常需强化免疫治疗且神经肌肉恢复可能较差;文中讨论了肌MRI及抗HMGCR、抗SRP抗体在诊断中的作用并回顾现有治疗推荐。

要点

  • IMNM表现为进行性近端无力,肌外表现少,组织学见显著肌坏死与肌纤维再生、肌内淋巴细胞相对稀少。
  • 抗HMGCR与抗SRP抗体及肌MRI是诊断评估的重要组成部分。
  • 疾病常较重、神经肌肉恢复可能不佳,常需强化免疫治疗。

核心结论

  • 免疫介导坏死性肌病是较新描述的特发性炎症性肌病亚型,免疫机制被认为参与发病,疾病常严重且恢复可能较差。
  • 近年国际研究在特异性自身抗体、危险因素、临床特征、治疗选择及新型分类标准方面取得重要进展,但许多问题仍未知。

研究设计与样本

  • 本文为叙述性综述,汇总当前关于IMNM病理生理、临床表现、组织学特征与血清学特点的证据。
  • 综述范围包括诊断方法(肌MRI及针对HMGCR和SRP的抗体)与现有治疗推荐。

主要发现

  • IMNM以进行性近端肌无力为特征,肌外表现较少。
  • 组织学可见显著肌坏死、肌纤维再生及肌内淋巴细胞相对稀少。
  • 免疫机制被认为参与发病,且常需强化免疫治疗。
  • 疾病常严重,神经肌肉恢复可能较差。

临床怎么用

  • 诊断评估可结合肌MRI与针对HMGCR、SRP的自身抗体检测。
  • 治疗上常需强化免疫治疗,并按现有治疗推荐管理。

局限性

  • 原文指出该病许多方面仍未知,证据主要来自观察性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune-mediated necrotising myopathy (IMNM) is a relatively recently described form of idiopathic inflammatory myopathy (IIM) that is characterised by progressive proximal weakness and few extra-muscular manifestations. Prominent myonecrosis, muscle fibre regeneration and a relative paucity of intramuscular lymphocytes are seen histologically. Immunological mechanisms are believed to underpin the pathogenesis, and intense immunotherapy is frequently required. Disease is often severe and neuromuscular recovery may be poor. Recently there has been an impressive international research effort to understand and characterise this emerging condition, although much remains unknown. Significant advances in the field include the discovery of specific autoantibodies, increased understanding of the risk factors, clinical characteristics and treatment options owing to a wealth of observational studies, and the development of novel classification criteria. Herein we review the current evidence regarding the pathophysiology, clinical presentation, histological features and serological profiles associated with this condition. Diagnostic approaches are discussed, including the role of muscle MRI and antibodies targeting 3‑hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and signal-recognition peptide (SRP), and a review of current treatment recommendations is provided.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Day JA, Limaye V. Immune-mediated necrotising myopathy: A critical review of current concepts. Semin Arthritis Rheum. 2019. PMID: 31109639. doi:10.1016/j.semarthrit.2019.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。